Semaglutide and tirzepatide are the two most talked-about weight-loss and diabetes medications, and they are easy to confuse. They are not the same drug, they do not work the same way, and in head-to-head testing they did not produce identical results. Here is a clear, evidence-based comparison.
Quick answer: Semaglutide is a single-hormone GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus). Tirzepatide is a dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound), meaning it activates two gut hormone receptors instead of one. In the SURMOUNT-5 head-to-head trial published in 2025, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. Both are effective weekly injections; tirzepatide delivered more weight loss on average, while semaglutide has a longer track record. The right choice depends on your goals, tolerance, and what your clinician recommends.
Semaglutide vs tirzepatide: mechanism of action
This is the core difference.
- Semaglutide mimics GLP-1, a hormone that increases insulin when blood sugar rises, slows stomach emptying, and reduces appetite signaling in the brain. One receptor, one pathway.
- Tirzepatide mimics two hormones, GLP-1 and GIP. Adding GIP activity appears to enhance the appetite and metabolic effects, which is the leading explanation for the larger weight loss seen with tirzepatide.
So tirzepatide is a dual-receptor agonist and semaglutide is a single-receptor agonist. That mechanistic difference is why the two are not interchangeable and why their results differ.
Difference between semaglutide and tirzepatide at a glance
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Maker | Novo Nordisk | Eli Lilly |
| Weight loss (SURMOUNT-5 head-to-head) | 13.7% average | 20.2% average |
| Form | Weekly injection (Rybelsus is oral) | Weekly injection |
| Diabetes trials | SUSTAIN program | SURPASS program |
| Weight-loss trials | STEP program | SURMOUNT program |
Figures are averages from the trials each drug was studied in and vary by dose and study.
Is tirzepatide better than semaglutide?
On weight loss specifically, the evidence leans toward tirzepatide. In SURMOUNT-5, the head-to-head trial published in 2025, participants on tirzepatide lost 20.2% of body weight on average versus 13.7% on semaglutide, roughly 47% greater weight loss. That does not make it "better" for everyone. Semaglutide has a longer real-world track record, may be better tolerated by some, and is sometimes more accessible or affordable depending on coverage and supply. "Better" depends on your weight-loss target, side-effect tolerance, cost, and whether you have type 2 diabetes.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Is Wegovy better than tirzepatide?
Wegovy is the weight-loss brand of semaglutide. Comparing Wegovy to tirzepatide (Zepbound) is the same semaglutide-vs-tirzepatide question with brand names attached. In SURMOUNT-5, tirzepatide produced more weight loss on average (20.2% vs 13.7%), but Wegovy remains a proven, FDA-approved option. Tolerability and individual response matter, some people do better on one than the other regardless of the averages.
Side effects: similar profile, different intensity
Both drugs share a gastrointestinal side-effect profile, nausea, vomiting, diarrhea, constipation, and reduced appetite, most common when starting or increasing the dose. These usually ease with slow titration. Because tirzepatide is generally more potent, some people find its effects more pronounced. Starting low and stepping up gradually is the standard way to limit side effects for both.
Which should you choose?
Talk with a licensed clinician, but the general logic is: if maximum average weight loss is the priority and you tolerate it, tirzepatide often comes out ahead; if you value a longer track record or it is more accessible to you, semaglutide is a strong choice. If you want to compare supervised programs for either medication on cost and clinical oversight, FormBlends' provider comparison tool lets you line them up, and our compounded semaglutide page explains how a supervised GLP-1 program is structured.
FAQs
What is the main difference between semaglutide and tirzepatide? Semaglutide targets one hormone receptor (GLP-1); tirzepatide targets two (GIP and GLP-1), which is linked to its larger average weight loss.
Is tirzepatide stronger than semaglutide? On average, tirzepatide produced greater weight loss in the head-to-head SURMOUNT-5 trial, but individual results vary.
Are semaglutide and tirzepatide the same? No. They are different molecules with different mechanisms, made by different companies.
Is Wegovy better than tirzepatide? Wegovy is semaglutide for weight loss. Tirzepatide showed more average weight loss in trials, but Wegovy is proven and may suit some people better.
Do they have the same side effects? Both cause mainly gastrointestinal effects. Tirzepatide's can feel more pronounced because it is generally more potent.
Which is better for type 2 diabetes? Both lower blood sugar effectively; the SURPASS (tirzepatide) and SUSTAIN (semaglutide) programs support each. Your clinician decides based on your profile.
Can I switch from one to the other? Yes, under clinical supervision, with re-titration. Do not switch on your own.
Are both weekly injections? Yes, semaglutide and tirzepatide injections are weekly. Rybelsus is a daily oral semaglutide tablet.
Sources
- Eli Lilly, SURMOUNT-5 head-to-head results (2025): https://investor.lilly.com/news-releases
- NEJM / STEP and SURMOUNT trial publications overview: https://www.nejm.org/
- FDA prescribing information for Wegovy and Zepbound: https://www.accessdata.fda.gov/scripts/cder/daf/
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →